Clinical Research Directory
Browse clinical research sites, groups, and studies.
Safety and Efficacy of Low-dose Anticoagulation With Argatroban and Enoxaparin on ECMO
Sponsor: University Hospital Ostrava
Summary
The standard and most common therapy is anticoagulation with heparin according to activated partial thromboplastin time (aPTT) during extracorporeal membrane oxygenation (ECMO) support. The study will focus on evaluating the efficacy and safety of new anticoagulants on ECMO, namely argatroban and enoxaparin in lower doses controlled according to targeted antiIIa and antiXa markers.
Official title: Low-dose Versus Standard-dose Anticoagulation With Argatroban and Enoxaparin During Extracorporeal Membrane Oxygenation Controlled by Anti-IIa and An-ti-Xa, Respectively
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
200
Start Date
2027-01
Completion Date
2029-12
Last Updated
2026-04-02
Healthy Volunteers
No
Conditions
Interventions
Low anticoagulation dose of argatroban and enoxaparin during ECMO
Study subjects in this group will receive low anticoagulation dose of argatroban and enoxaparin during ECMO
Standard anticoagulation dose of argatroban and enoxaparin during ECMO
Study subjects in this group will receive standard anticoagulation dose of argatroban and enoxaparin during ECMO
Locations (2)
University Hospital Ostrava
Ostrava, Moravian-Silesian Region, Czechia
University Hospital Motol
Prague, Czechia